key: cord-0752202-6xaqp0oq
authors: Hendin, Ariel; Castellucci, Lana; Rosenberg, Hans
title: Just the facts: how to assess for cerebral venous thrombosis
date: 2021-08-24
journal: CJEM
DOI: 10.1007/s43678-021-00194-9
sha: 4144c3f1d2a8e47f702aa14c27259576eff00adc
doc_id: 752202
cord_uid: 6xaqp0oq

nan

CVT occurs when blood clots form in the cerebral cortical veins or dural venous sinuses. This leads to increased intracranial pressure, cerebral edema, and infarction of brain tissue, which can subsequently hemorrhage. CVT accounts for 0.5-1% of all stroke diagnoses. While this is a rare disease, affecting approximately five patients per million yearly, a delayed diagnosis of CVT can lead to significant morbidity and mortality. CVT is more common among younger patients, with a median age of 33-37 years, and the majority are female (in a 3:1 ratio).

CVT can manifest in multiple ways. Most patients (90%) report persistent headache, but some will present with seizure, or with focal neurological deficits that will vary based on the region of venous occlusion. A minority of patients with CVT will present with confusion as a predominant symptom if they have developed cerebral edema [1, 2] .

CVT is a thrombotic disease of the venous system of the brain, and 75-85% of patients carry at least one typical risk factor for thromboembolism. Risk factors in order of decreasing frequency include oral contraceptive use or hormone replacement therapy, pregnancy, postpartum state, acquired/hereditary thrombophilia, and local trauma or inflammation, such as a head and neck infection or surgery [1] . Systemic diseases, such as cancer, inflammatory bowel disease, and vasculitides, are also associated with CVT.

reported within 4-28 days of vaccination. The incidence of VITT ranges from 1 in 26,000 to 1 in 100,000. There has not been any association reported between typical venous thromboembolism risk factors and increased risk of VITT [3] .

No lab test can rule out the diagnosis of CVT. While a D-dimer assay is highly sensitive for pulmonary embolism and deep venous thrombosis, its use in CVT is less well defined. The D-dimer had a sensitivity of 89% in a recent meta-analysis of patients with CVT [4] , but false negative results are seen particularly in patients with prolonged symptom duration (greater than 1 week) or with headache alone in the absence of other findings. This means that physicians in low-resource or rural settings without access to advanced imaging modalities will have to consider transfer of patients for definitive exclusion or confirmation of diagnosis.

Despite the limited utility of blood tests in CVT, plain computed tomography (CT) head is helpful as a first test. Non-contrast CT may show abnormalities consistent with CVT in up to 1/3 of cases, including a hyperdense cortical vein or dural sinus, or foci of intracranial hemorrhage. However, the majority of non-contrast CT scans are normal in patients with CVT, and further testing must be pursued in a patient with high clinical suspicion [2] . Magnetic Resonance Venogram (MRV) is the gold standard for diagnosis. The sensitivity of CT venogram (CTV), based on small studies, is nearly as good as MRV (and likely more accessible in the ED) [4] . Classic findings on CTV include venous sinus rim enhancement and a central filling defect. In patients with a high level of suspicion for CVT after a nondiagnostic CTV, MRV should be considered.

If there is a specific concern for CVT in the context of recent adenoviral vector COVID vaccine, the first test should be a complete blood count. VITT is much less likely with a platelet count > 150 × 10 9 /L. Alternative diagnoses (including CVT unrelated to VITT, in a patient with clinical features or risk factors) should be considered [3] . Additional investigations for VITT diagnosis should be discussed with a Thrombosis expert.

All CVT patients, including those with intracerebral hemorrhage, should be started on low molecular weight heparin unless contraindicated due to renal insufficiency or if rapid reversal is necessary for surgical intervention. These latter patients should receive intravenous unfractionated heparin. Long-term management typically consists of warfarin, as there is limited evidence for direct oral anticoagulants, but these decisions are made with Thrombosis consultation.

Patients with increased intracranial pressure causing headache should receive analgesia and antiemetics. Patients with severe intracranial hypertension with signs of impending herniation on imaging should be referred for decompressive surgery. Antiepileptic medications should be started for CVT patients presenting with seizure. Steroids should not be used unless indicated for an accompanying inflammatory condition. Thrombolytics and endovascular therapy are not recommended [1, 2, 4, 5] .

For patients with VITT and associated CVT, treatment involves avoiding heparin-based anticoagulants and platelet transfusions, and management should be discussed with a Thrombosis expert [3] . If VITT is suspected post-COVID vaccine, this should also be reported to the local public health agency.

Cerebral venous thrombosis: a practical guide

Diagnosis and management of cerebral venous thrombosis: a statement for healthcare professionals from the American Heart Association/ American Stroke Association

Vaccine-induced immune thrombotic thrombocytopenia (VITT) following adenovirus vector COVID-19 vaccination

European Stroke Organization guideline for the diagnosis and treatment of cerebral venous thrombosis-endorsed by the European Academy of Neurology

Anticoagulation for cerebral venous sinus thrombosis. Cochrane Database Syst Rev